Vitamin D and systemic cancer: Is this relevant to malignant melanoma?

British Journal of Dermatology

Volumn 147, Issue 2, 2002, Pages 197-213

  Osborne, J E ^a   Hutchinson, P E ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CELL NUCLEUS RECEPTOR; CERAMIDE; COLECALCIFEROL; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS ANTIGEN; METALLOPROTEINASE; OXYGENASE; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; SERINE PROTEINASE; SOMATOMEDIN RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOSYNTHESIS; CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER INHIBITION; CANCER INVASION; CATABOLISM; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; DISEASE ASSOCIATION; DRUG EFFECT; ENZYME INHIBITION; GENE EXPRESSION; GENE TARGETING; GENETIC POLYMORPHISM; GROWTH REGULATION; HUMAN; HYDROXYLATION; MELANOCYTE; MELANOMA; METASTASIS; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOLAR RADIATION; VITAMIN BLOOD LEVEL; VITAMIN D METABOLISM;

BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL DIVISION; CHOLECALCIFEROL; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MELANOMA; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS; VITAMIN D;

EID: 0036380878     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2002.04960.x     Document Type: Review

References (181)

1. 3. In: Vitamin D Endocrine System. Structural, Biological, Genetic and Clinical Aspects (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 2000; 159-62.
2. 3 (calcitriol). J Dermatol Sci 1998; 18: 118-27.
3. 3. Biochemistry 1986; 25: 1545-8.
4. Holick MF. The D-lemma: how much vitamin D is enough for bone and cellular health?. In: Vitamin D Endocrine System. Structural, Biological, Genetic and Clinical Aspects (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 2000; 923-8.
5. Schuster I, Egger H, Herzig G et al. Constitutive activity of 1α-hydroxylase in primary human keratinocytes (HK), revealed by selective inhibition of CYP24. In: Vitamin D Endocrine System. Structural, Biological, Genetic and Clinical Aspects (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 2000; 182-5.
6. 3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 1999; 140: 2071-6.
7. Baker AR, McDonnell DP, Hughes M et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 1988; 85: 3294-8.
8. 3 receptor and its chromosomal gene. In: The Steroid/Thyroid Hormone Receptor Family and Gene Regulation (Gustafsoen JA, ed.). Basel: Birkhauser Verlag, 1989; 147-59.
9. Miyamoto K, Kesterson RA, Yamamoto H et al. Structural organisation of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol 1997; 11: 1165-79.
10. Gross C, Eccleshall TR, Malloy PJ et al. The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J Bone Miner Res 1996; 11: 1850-5.
11. Minamitani K, Takahashi Y, Minagawa M et al. Exon 2 polymorphism in the human vitamin D receptor gene is a predictor of peak bone density. J Bone Miner Res 1996; 11 (Suppl. 1): 207 [Abstr.].
12. Saijo T, Ito M, Takeda E et al. A unique mutation in the vitamin D receptor gene in three Japanese patients with vitamin D-dependent rickets type II: utility of single strand conformation polymorphism analysis for heterozygous carrier detection. Am J Hum Genet 1991; 49: 668-73.
13. Whitfield GK, Remus LS, Jurutka PW et al. Are human vitamin D receptor gene polymorphisms functionally significant? In: Vitamin D Endocrine System. Structural, Biological, Genetic and Clinical Aspects (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 2000; 817-23.
14. Gross C, Krishnan AV, Malloy PJ et al. The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants. J Bone Miner Res 1998; 13: 1691-9.
15. 3 on intestinal calcium uptake. Proc Natl Acad Sci USA 1975; 72: 229-30.
16. Nemere I, Szego CM. Early actions of parathyroid hormone and 1,25-dihydroxycholecalciferol on isolated epithelial cells from rat intestine: II. Analyses of additivity, contribution of calcium, and modulatory influence of indomethacin. Endocrinology 1981; 109: 2180-7.
17. Hance KW, Nemere I, Fleet JC. Cross-talk between non-genomic actions of calcitriol and nuclear vitamin D receptor function. In: Abstracts. The Eleventh Workshop on Vitamin D. Nashville, TN: Riverside California, 2000; 101 [Abstr.].
18. 3 and related analogs. In: Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 1997; 339-46.
19. 3. In: Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 1997; 361-74.
20. 3-mediated signal transduction for genomic and rapid biological responses is dependent upon the conformation of the signalling ligand. In: Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 1997; 331-8.
21. de Boland AR, Nemere I. Rapid actions of vitamin D compounds. J Cell Biochem 1992; 49: 32-6.
22. de Boland AR, Boland RL. Non-genomic signal transduction pathway of vitamin D in muscle. Cell Signal 1994; 6: 717-24.
23. 3 in rat intestine. Cell Signal 1996; 8: 153-7.
24. Facchinetti MM, Boland R, de Boland AR. Age-related loss of calcitriol stimulation of phosphoinositide hydrolysis in rat skeletal muscle. Mol Cell Endocrinol 1998; 136: 131-8.
25. Le Mellay V, Grosse B, Lieberherr M. Calcitriol uses a pertussis toxin-insensitive G-protein coupled to phospholipase C beta1 and estradiol a pertussis-sensitive G-protein coupled to phospholipase C beta2. In: Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 1997; 385-6.
26. 3 of the adenylyl cyclase/cyclic AMP pathway in rat and chick myoblasts. Biochim Biophys Acta 1995; 1269: 91-7.
27. 3. Mol Cell Endocrinol 1993; 90: 231-8.
28. Santillan G, Boland R. Protein kinase A-mediated membrane protein phosphorylation induced by calcitriol in cardiac muscle cells and tissue. In: Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 1997; 383-4.
29. 3 on growth zone and resting zone chondrocyte membrane alkaline phosphatase and phospholipase-A2 specific activities. Endocrin-ology 1988; 123: 2878-84.
30. 3 in three osteoblast-like cell lines (MC-3T3-E1, ROS 17/2.8, and MG-63). Bone 1992; 13: 51-8.
31. Schwartz Z, Swain LD, Kelly DW et al. Regulation of prostaglandin E2 production by vitamin D metabolites in growth zone and resting zone chondrocyte cultures is dependent on cell maturation. Bone 1992; 13: 395-401.
32. 3 and cell growth in monocytic U937 and Mono Mac 6 cells. Cell Biochem Funct 1995; 13: 19-23.
33. 3 protects human leukemic cells from tumor necrosis factor-induced apoptosis via inactivation of cytosolic phospholipase A2. Cancer Res 1998; 58: 633-40.
34. 3-mediated rapid stimulation of intestinal calcium transport (transcaltachia). Endocrinology 1990; 127: 39-45.
35. Facchinetti MM, Boland R, de Boland AR. Calcitriol transmembrane signalling: regulation of rat muscle phospholipase D activity. J Lipid Res 1998; 39: 197-204.
36. 3 on protein kinase C, in chondrocytes are mediated by phospholipase A2 and arachidonic acid. In: Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 1997; 353-60.
37. 3-stimulated Egr induction. J Biol Chem 1995; 270: 3642-7.
38. 3 regulation of calcium uptake by cultured myocytes. Cell Signal 1994; 6: 531-8.
39. 2+ transport). Endocrinology 1990; 127: 2475-80.
40. 2+ and apoptosis in breast cancer cell lines. In: Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 1997; 473-4.
41. 3-dependent protein phosphorylation in cardiac muscle. J Mol Cell Cardiol 1998; 30: 225-33.
42. 2D regulation of epidermal differentiation. In: Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 1997; 543-50.
43. 3 is mediated by mutual modulation of receptor expression. Eur J Cancer 1998; 34: 2119-25.
44. 3 in normal human keratinocytes. J Invest Dermatol 1996; 106: 1212-17.
45. 3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br J Haematol 2000; 109: 576-83.
46. 3-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem 2001; 276: 26365-73.
47. Reitsma PH, Rothberg PG, Astrin SM et al. Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite. Nature 1983; 306: 492-4.
48. 3 on normal human keratinocytes cultured in serum-free medium. Biochem Biophys Res Commun 1990; 166: 916-23.
49. Bektas M, Orfanos CE, Geilen CC. Different vitamin D analogues induce sphingomyelin hydrolysis and apoptosis in the human keratinocyte cell line HaCaT. Cell Mol Biol (Noisy-le-Grand) 2000; 46: 111-19.
50. Walker GJ, Hussussian CJ, Flores JF et al. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet 1995; 4: 1845-52.
51. Soufir N, Avril MF, Chompret A et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998; 7: 209-16.
52. Piccinin S, Doglioni C, Maestro R et al. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int J Cancer 1997; 74: 26-30.
53. Ohta M, Berd D, Shimizu M et al. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int J Cancer 1996; 65: 762-7.
54. Robinson WA, Elefanty AG, Hersey P. Expression of the tumour suppressor genes p15 and p16 in malignant melanoma. Melanoma Res 1996; 6: 285-9.
55. INK4b tumour suppressor genes in a subset of human sporadic cutaneous malignant melanoma. Br J Dermatol 1998; 138: 13-21.
56. Wolfel T, Hauer M, Schneider J et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269: 1281-4.
57. Kawa S, Nikaido T, Aoki Y et al. Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. Br J Cancer 1997; 76: 884-9.
58. 3 on the cell cycle genes, cyclin D1, 21 and p27 in MCF-7 cells. Mol Cell Endocrinol 1998; 142: 57-65.
59. 3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996; 10: 142-53.
60. 3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998; 139: 1197-207.
61. 3 increases transforming growth factor and transforming growth factor receptor type I and II synthesis in human bone cells. Biochem Biophys Res 1997; 239: 734-9.
62. 3 involves cell cycle arrest in G1 that is preceded by a transient proliferative burst and an increase in cyclin expression. Blood 1999; 93: 2721-9.
63. 3) inhibits the growth of squamous cell carcinoma and down-modulates p21 (Waf1/Cip1) in vitro and in vivo. Cancer Res 1999; 59: 2644-9.
64. Pringle JH, Fletcher A, Primrose L, Hutchinson PE. A quantitative reverse transcriptase polymerase chain reaction (RT-PCR): its use in measuring vitamin D receptor gene expression. In: Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 1997; 318-19.
65. 3. Endocrinology 1983; 113: 1950-7.
66. 3 induces maturation of the human monocyte cell line U937, and, in association with a factor from human T lymphocytes, augments production of the monokine, mononuclear cell factor. J Clin Invest 1984; 73: 731-9.
67. Orcel P, Bielakoff J, de Vernejoul MC. Formation of multinucleated cells with osteoclast precursor features in human cord monocytes cultures. Anat Rec 1990; 226: 1-9.
68. Hennings H, Michael D, Cheng C et al. Calcium regulation of growth and differentiation of mouse epidermal cells in culture. Cell 1980; 19: 245-54.
69. Menon GK, Grayson S, Elias PM. Ionic calcium reservoirs in mammalian epidermis: ultrastructural localization by ion-capture cytochemistry. J Invest Dermatol 1985; 84: 508-12.
70. 3. J Cell Physiol 1991; 146: 94-100.
71. Ng DC, Su MJ, Kim R, Bikle DD. Regulation of involucrin gene expression by calcium in normal human keratinocytes. Front Biosci 1996; 1: A16-24.
72. Polakowska RR, Graf BA, Falciano V, LaCelle P. Transcription regulatory elements of the first intron control human transglutaminase type I gene expression in epidermal keratinocytes. J Cell Biochem 1999; 73: 355-69.
73. 3: role of protein kinase C translocation. Biochem Biophys Res Commun 1989; 163: 1517-22.
74. Wakita H, Tokura Y, Yagi H et al. Keratinocyte differentiation is induced by cell-permeant ceramides and its proliferation is promoted by sphingosine. Arch Dermatol Res 1994; 286: 350-4.
75. Sayama K, Hanakawa Y, Shirakata Y et al. Apoptosis signal-regulating kinase 1 (ASK1) is an intracellular inducer of keratinocyte differentiation. J Biol Chem 2001; 276: 999-1004.
76. 3: mechanisms and clinical aspects. In: Vitamin D Endocrine System. Structural, Biological, Genetic and Clinical Aspects (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 2000; 477-84.
77. Xie SP, James SY, Colston KW, Vitamin D derivatives inhibit the mitogenic effects of IGF-I on MCF-7 human breast cancer cells. J Endocrinol 1997; 154: 495-504.
78. Colston KW, Perks CM, Xie SP, Holly JM. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol 1998; 20: 157-62.
79. Nickerson T, Huynh H, Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. J Endocrinol 1999; 160: 223-9.
80. 3 potentiates the cytotoxic effect of TNF on human breast cancer cells. Mol Cell Endocrinol 1994; 106: 157-62.
81. Johnson CS, Hershberger PA, Modzelewski RA et al. 1,25 Dihydroxycholecalciferol (calcitriol) as an anticancer agent: preclinical studies. In: Vitamin D Endocrine System. Structural, Biological, Genetic and Clinical Aspects (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 2000; 461-8.
82. Narvaez CJ, Waterfall T, Welsh J. Role of mitochondria and caspases in vitamin D mediated apoptosis in MCF-7 breast cancer cells. In: Vitamin D Endocrine System. Structural, Biological, Genetic and Clinical Aspects (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 2000; 383-6.
83. 3 and its receptor in mammary gland: from normal development to breast cancer. In: Vitamin D Endocrine System. Structural, Biological, Genetic and Clinical Aspects (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 2000; 453-60.
84. Muller-Wieprecht V, Riebeling C, Stooss A, Orfanos CE. Bcl-2 transfected HaCaT keratinocytes resist apoptotic signals of ceramides, tumor necrosis factor alpha and 1alpha, 25-dihydroxy-vitamin D. Arch Dermatol Res 2000; 292: 455-62.
85. 3. Biochem Biophys Res Commun 1998; 251: 868-73.
86. Xia Z, Dickens M, Raingeaud J et al. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270: 1326-31.
87. Verheij M, Bose R, Lin XH et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996; 380: 75-9.
88. Fan M, Goodwin M, Vu T et al. Vinblastine-induced phosphorylation of bcl-2 and bcl-XL is mediated by JNK and occurs in parallel with inactivation of the raf-1/MEK/ERK cascade. J Biol Chem 2000; 275: 29980-5.
89. Shaulian E, Schreiber M, Piu F et al. The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest. Cell 2000; 103: 897-907.
90. Sergeev IN, Rhoten WB. Regulation of intracellular calcium in human breast cancer cells. Endocrine 1998; 9: 321-7.
91. 3 on ultraviolet light B-induced damage in keratinocyte and its mechanism of action. J Dermatol Sci 1998; 18: 11-18.
92. Mason RS, Holliday CJ. 1,25 Dihydroxyvitamin D contributes to photoprotection in skin cells. In: Vitamin D Endocrine System. Structural, Biological, Genetic and Clinical Aspects (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 2000; 605-8.
93. 3, and granulocyte-macrophage colony-stimulating factor. Blood 1997; 90: 4578-87.
94. 3 inhibits the activation of C-JUN N-terminal kinase by physiological and environmental stresses in keratinocytes. In: Vitamin D Endocrine System. Structural, Biological, Genetic and Clinical Aspects (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 2000; 621-2.
95. 3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. J Invest Dermatol 2001; 117: 1241-9.
96. 3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 1994; 12: 195-202.
97. Schwartz GG, Wang MH, Zang M et al. 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 1997; 6: 727-32.
98. 3 reduces tumor motility and metastasis. Invasion Metastasis 1993; 13: 169-77.
99. Konety BR, Lavelle JP, Pirtskalaishvili G et al. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol 2001; 165: 253-8.
100. 3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ 2000; 11: 221-9.
101. 3 inhibits tenascin-C expression in mammary epithelial cells. FEBS Lett 1998; 426: 225-8.
102. 3 on normal and tumor derived murine endothelial cells. In: Abstracts. The Eleventh Workshop on Vitamin D. Nashville, TN: Riverside California, 2000; 92 [Abstr.].
103. 3 inhibits angiogenesis in vitro and in vivo. Circ Res 2000; 87: 214-20.
104. 3 is a potent inhibitor of tumor cell-induced angiogenesis. J Invest Dermatol Symp Proc 1996; 1: 97-101.
105. Eisman JA, Martin TJ, MacIntyre I, Moseley JM. 1,25-Dihydroxyvitamin-D-receptor in breast cancer cells. Lancet 1979; ii: 1335-6.
106. 3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 1981; 108: 1083-6.
107. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132: 1952-60.
108. 3 on primary cultures of human prostatic cells. Cancer Res 1994; 54: 805-10.
109. 3 in seven human prostatic cancer cell lines. Clin Cancer Res 1995; 1: 997-1003.
110. 3 metabolites. Cancer Res 1983; 43: 4443-7.
111. 3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20). J Steroid Biochem 1986; 24: 373-6.
112. Colston KW, Chander SK, Mackay AG, Coombes RC. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 1992; 44: 693-702.
113. Cross HM, Pavelka M, Slavik J, Peterlik M. Growth control of human colon cancer cells by vitamin D and calcium in vitro. J Natl Cancer Inst 1992; 84: 1355-7.
114. 3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 1993; 53: 3712-18.
115. 3 on proliferation and differentiation of CaCo-2 cells. Endocrinology 1994; 134: 1710-17.
116. 3: in vivo and in vitro effects on human preleukaemic and leukaemic cells. Cancer Treat Rep 1985; 69: 1399-407.
117. 3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J Cell Biol 1984; 98: 391-8.
118. 3. Proc Natl Acad Sci USA 1981; 78: 4990-4.
119. 3 on the morphology of human breast cancer cell line BT20. Differentiation 1989; 40: 63-9.
120. 3 derivatives on growth, differentiation and apoptosis in tumoral colonic HT 29 cells: possible implication of intracellular calcium. Cancer Lett 1995; 97: 99-106.
121. 3. Cancer Res 1987; 47: 21-5.
122. Getzenberg RH, Light BW, Lapco PE et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997; 50: 999-1006.
123. 3 resistant variant. In: Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 1997; 461-2.
124. 3 on proliferation of cancer cells in vitro. Cancer Lett 1997; 120: 65-9.
125. Flanagan L, Ethier S, Welsh J. Vitamin D induced apoptosis in oestrogen independent breast cancer cells and tumours. In: Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 1997; 142.
126. 3 analog, EB1089. Endocrinology 1998; 139: 2102-10.
127. Blutt SE, Polek TC, Stewart LV et al. A calcitriol analog, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res 2000; 60: 779-82.
128. Beaty MM, Lee EY, Glauert HP. Influence of dietary calcium and vitamin D on colon epithelial cell proliferation and 1,2-dimethylhydrazine-induced colon carcinogenesis in rats fed high fat diets. J Nutr 1993; 123: 144-52.
129. 3 in chemically induced rat colon carcinogenesis. Carcinogenesis 1992; 13: 2293-8.
130. 3 inhibits phorbol ester-dependent chemical carcinogenesis in mouse skin. Biochem Biophys Res Commun 1983; 116: 605-11.
131. 3. Cancer Res 1985; 45: 5426-30.
132. Furst CJ, Auer G, Nordevang E et al. DNA pattern and dietary habits in patients with breast cancer. Eur J Cancer 1993; 29: 1285-8.
133. Garland C, Shekelle RB, Barrett-Connor E et al. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet 1985; i: 307-9.
134. Bostick RM, Potter JD, Sellers TA et al. Relation of calcium, vitamin D, and dairy food intake to incidence of colon cancer among older women. Am J Epidemiol 1993; 137: 1302-17.
135. Kearney J, Giovannucci E, Rimm EB et al. Calcium, vitamin D, and dairy foods and the occurrence of colon cancer in men. Am J Epidemiol 1996; 143: 907-17.
136. Garland FC, Garland CF, Gorham ED, Young JF. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 1990; 19: 614-22.
137. Gorham ED, Garland FC, Garland CF. Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 1990; 19: 820-4.
138. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer (hypothesis) ? Anticancer Res 1990; 10: 1307-12.
139. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Cancer 1992; 70: 2861-9.
140. Gorham ED, Garland CF, Garland FC. Acid haze air pollution and breast and colon cancer mortality in 20 Canadian cities. Can J Public Health 1989; 80: 96-100.
141. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 1980; 9: 227-31.
142. Kozlowski JM, Grayhack JT. Carcinoma of the prostate. In: Adult and Pediatric Urology (Gillenwater J, Grayhack J, Howards S, Duckett J, eds), 2nd edn. St Louis, MO: Mosby-Year Book, 1995; 1575-713.
143. Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 1994; 86: 705-12.
144. Studzinski GP, Moore DC. Sunlight - can it prevent as well as cause cancer? Cancer Res 1995; 55: 4014-22.
145. Breslow N, Chan CW, Dhom G et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977; 20: 680-8.
146. Luscombe CJ, Fryer AA, French ME et al. Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet 2001; 358: 641-2.
147. Luscombe CJ, French ME, Liu S et al. Outcome in prostate cancer associations with skin type and polymorphism in pigmentation-related genes. Carcinogenesis 2001; 22: 1343-7.
148. Janowsky EC, Hulka BS, Lester GE. Vitamin D levels as a risk for female breast cancer. In: Vitamin D. A Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical Applications (Norman AW, Bouillon R, Thomasset M, eds). Berlin: de Gruyter, 1994; 496-7.
149. Mawer EB, Walls J, Howell A et al. Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J Clin Endocrinol Metab 1997; 82: 118-22.
150. Corder EH, Guess HA, Hulka BS et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993; 2: 467-72.
151. Glass AR, Kikendall JW, Sobin LH, Bowen PE. Serum 25-hydroxyvitamin D concentrations in colonic neoplasia. Horm Metab Res 1993; 25: 397-8.
152. Garland CF, Comstock GW, Garland FC et al. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989; ii: 1176-8.
153. Ingles SA, Haile R, Henderson B et al. Association of vitamin D receptor genetic polymorphism with breast cancer risk in African-American and Hispanic women. In: Vitamin D. Chemistry, Biology and Clinical Applications of the Steroid Hormone (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 1997; 813-14.
154. Ingles SA, Ross RK, Yu MC et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997; 89: 166-70.
155. Taylor JA, Hirvonen A, Watson M et al. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996; 56: 4108-10.
156. Ingles SA, Coetzee GA, Ross RK et al. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 1998; 58: 1620-3.
157. Schwartz G. Prostate cancer and vitamin D: from concept to clinic. A ten-year update. In: Vitamin D Endocrine System. Structural, Biological, Genetic and Clinical Aspects (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 2000; 445-50.
158. Trump DL, Hershberger PA, Modzelewski RA et al. Clinical development of calcitriol and calcitriol analogs as anticancer agents. In: Vitamin D Endocrine System. Structural, Biological, Genetic and Clinical Aspects (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 2000; 469-75.
159. Evans TRJ, Hamberg KJ, Skov T et al. Seocalcitol (EB 1089) -clinical experience to date. In: Vitamin D Endocrine System. Structural, Biological, Genetic and Clinical Aspects (Norman AW, Bouillon R, Thomasset M, eds). Riverside, CA: University of California, 2000; 485-8.
160. 3 in human malignant melanoma cell lines. J Surg Res 1996; 61: 127-33.
161. 3, alpha-melanocyte stimulating hormone, and beta-estradiol. J Invest Dermatol 1988; 91: 593-8.
162. Mason RS, Pryke AM, Ranson M et al. Human melanoma cells: functional modulation by calciotropic hormones. J Invest Dermatol 1988; 90: 834-40.
163. 3 on epidermal melanocytes. J Cell Physiol 1988; 136: 273-80.
164. Mansur CP, Gordon PR, Ray S et al. Vitamin D, its precursors, and metabolites do not affect melanization of cultured human melanocytes. J Invest Dermatol 1988; 91: 16-21.
165. 3 and its analogues. Cell Death Differ 1998; 5: 946-52.
166. 3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma. J Lab Clin Med 1999; 133: 120-8.
167. 3 in human melanoma cells in vitro. Cell Adhes Commun 1998; 5: 109-20.
168. Cornwell ML, Comstock GW, Holick MF, Bush TL. Prediagnostic serum levels of 1,25-dihydroxyvitamin D and malignant melanoma. Photodermatol Photoimmunol Photomed 1992; 9: 109-12.
169. Hutchinson PE, Osborne JE, Lear JT et al. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 2000; 2: 498-504.
170. Green A, Siskind V. Geographical distribution of cutaneous melanoma in Queensland. Med J Aust 1983; 1: 407-10.
171. Crombie IK. Variation of melanoma incidence with latitude in North America and Europe. Br J Cancer 1979; 40: 774-81.
172. Jelfs PL, Giles G, Shugg D et al. Cutaneous malignant melanoma in Australia, 1989. Med J Aust 1994; 161: 182-7.
173. Holman CD, Armstrong BK. Pigmentary traits, ethnic origin, benign nevi, and family history as risk factors for cutaneous malignant melanoma. J Natl Cancer Inst 1984; 72: 257-66.
174. Holly EA, Aston DA, Cress RD et al. Cutaneous melanoma in women. II. Phenotypic characteristics and other host-related factors. Am J Epidemiol 1995; 141: 934-42.
175. Kaskel P, Sander S, Kron M et al. Outdoor activities in childhood: a protective factor for cutaneous melanoma? Results of a case-control study in 271 matched pairs. Br J Dermatol 2001; 145: 602-9.
176. Elwood JM, Gallagher RP, Hill GB, Pearson JC. Cutaneous melanoma in relation to intermittent and constant sun exposure - the Western Canada Melanoma Study. Int J Cancer 1985; 35: 427-33.
177. Osterlind A, Tucker MA, Stone BJ, Jensen OM. The Danish case-control study of cutaneous malignant melanoma. II. Importance of UV-light exposure. Int J Cancer 1988; 42: 319-24.
178. Holly EA, Aston DA, Cress RD et al. Cutaneous melanoma in women. I. Exposure to sunlight, ability to tan, and other risk factors related to ultraviolet light. Am J Epidemiol 1995; 141: 923-33.
179. Autier P, Dore JF, Schifflers E et al. Melanoma and use of sun-screens: an EORTC case-control study in Germany, Belgium and France. The EORTC Melanoma Cooperative Group. Int J Cancer 1995; 61: 749-55.
180. Westerdahl J, Olsson H, Mosback A et al. Is the use of sunscreens a risk factor for melanoma? Melanoma Res 1995; 5: 59-65.
181. Marks R, Foley PA, Jolley D et al. The effect of regular sunscreen use on vitamin D levels in an Australian population. Results of a randomized controlled trial. Arch Dermatol 1995; 131: 415-21.